Alps Advisors Inc. Has $5.29 Million Stake in Amgen Inc. $AMGN

Alps Advisors Inc. raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 63.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 18,759 shares of the medical research company’s stock after buying an additional 7,254 shares during the period. Alps Advisors Inc.’s holdings in Amgen were worth $5,294,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. TAGStone Capital Inc. boosted its position in Amgen by 0.8% during the third quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after purchasing an additional 32 shares during the last quarter. Wealth Quarterback LLC raised its stake in shares of Amgen by 1.6% during the 3rd quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock worth $624,000 after purchasing an additional 34 shares in the last quarter. DDFG Inc boosted its holdings in shares of Amgen by 1.1% in the 3rd quarter. DDFG Inc now owns 3,014 shares of the medical research company’s stock valued at $850,000 after buying an additional 34 shares during the last quarter. Nicholson Wealth Management Group LLC grew its stake in shares of Amgen by 0.6% in the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock valued at $1,652,000 after buying an additional 35 shares in the last quarter. Finally, Crown Wealth Group LLC increased its holdings in Amgen by 4.0% during the third quarter. Crown Wealth Group LLC now owns 910 shares of the medical research company’s stock worth $257,000 after buying an additional 35 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Down 2.2%

Shares of AMGN opened at $375.82 on Tuesday. The firm has a market cap of $202.37 billion, a P/E ratio of 26.41, a price-to-earnings-growth ratio of 3.96 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $385.12. The firm’s 50-day simple moving average is $335.21 and its 200 day simple moving average is $311.98.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the previous year, the company posted $5.31 earnings per share. The business’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is currently 66.90%.

Insiders Place Their Bets

In related news, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,908 shares of company stock worth $3,674,966 in the last 90 days. Company insiders own 0.69% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on AMGN shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Argus raised their target price on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Friday. The Goldman Sachs Group lifted their price target on Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Leerink Partners boosted their price target on Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Finally, DZ Bank raised their price objective on Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $351.65.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.